AR and prostate carcinoma: To first compare the transcriptomic changes associated with proxalutamide and enzalutamide, RNA-sequencing (RNA-Seq) analysis was carried out in AR-positive prostate cancer Lymph Node Carcinoma of the Prostate (LNCaP) cells using either 20 μM proxalutamide or enzalutamide for 8 h of treatment.